• Je něco špatně v tomto záznamu ?

Long-term Prolonged-release Tacrolimus-based Immunosuppression in De Novo Kidney Transplant Recipients: 5-Y Prospective Follow-up of Patients in the ADVANCE Study

V. Pernin, M. Glyda, O. Viklický, A. Lõhmus, L. Wennberg, O. Witzke, B. von Zur-Mühlen, S. Anaokar, M. Hurst, G. Kazeem, N. Undre, DRJ. Kuypers

. 2023 ; 9 (3) : e1432. [pub] 20230208

Status neindexováno Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23002780

UNLABELLED: Although prolonged-release tacrolimus (PR-T) is widely approved for posttransplantation immunosuppression in kidney recipients, large-scale studies are required to assess long-term outcomes. We present follow-up data from the Advagraf-based Immunosuppression Regimen Examining New Onset Diabetes Mellitus in Kidney Transplant Recipients (ADVANCE) trial, in which kidney transplant patients (KTPs) received corticosteroid minimization with PR-T. METHODS: ADVANCE was a 24-wk, randomized, open-label, phase-4 study. De novo KTPs received PR-T with basiliximab and mycophenolate mofetil and were randomized to receive an intraoperative corticosteroid bolus plus tapered corticosteroids until day 10 (arm 1) or an intraoperative corticosteroid bolus (arm 2). In this 5-y, noninterventional follow-up, patients received maintenance immunosuppression according to standard practice. The primary endpoint was graft survival (Kaplan-Meier). Secondary endpoints included patient survival, biopsy-confirmed acute rejection-free survival, and estimated glomerular filtration rate (4-variable modification of diet in renal disease). RESULTS: Follow-up study included 1125 patients. Overall graft survival at 1 and 5 y posttransplantation was 93.8% and 88.1%, respectively, and was similar between treatment arms. At 1 and 5 y, patient survival was 97.8% and 94.4%, respectively. Five-year graft and patient survival rates in KTPs who remained on PR-T were 91.5% and 98.2%, respectively. Cox proportional hazards analysis demonstrated similar risk of graft loss and death between treatment arms. Five-year biopsy-confirmed acute rejection-free survival was 84.1%. Mean ± standard deviation values of estimated glomerular filtration rate were 52.7 ± 19.5 and 51.1 ± 22.4 mL/min/1.73 m2 at 1 and 5 y, respectively. Fifty adverse drug reactions were recorded, probably tacrolimus-related in 12 patients (1.5%). CONCLUSIONS: Graft survival and patient survival (overall and for KTPs who remained on PR-T) were numerically high and similar between treatment arms at 5 y posttransplantation.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23002780
003      
CZ-PrNML
005      
20230421100112.0
007      
ta
008      
230413s2023 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/TXD.0000000000001432 $2 doi
035    __
$a (PubMed)36875940
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pernin, Vincent $u Department of Nephrology, Dialysis and Transplantation, Hôpital Lapeyronie, University of Montpellier, Montpellier, France
245    10
$a Long-term Prolonged-release Tacrolimus-based Immunosuppression in De Novo Kidney Transplant Recipients: 5-Y Prospective Follow-up of Patients in the ADVANCE Study / $c V. Pernin, M. Glyda, O. Viklický, A. Lõhmus, L. Wennberg, O. Witzke, B. von Zur-Mühlen, S. Anaokar, M. Hurst, G. Kazeem, N. Undre, DRJ. Kuypers
520    9_
$a UNLABELLED: Although prolonged-release tacrolimus (PR-T) is widely approved for posttransplantation immunosuppression in kidney recipients, large-scale studies are required to assess long-term outcomes. We present follow-up data from the Advagraf-based Immunosuppression Regimen Examining New Onset Diabetes Mellitus in Kidney Transplant Recipients (ADVANCE) trial, in which kidney transplant patients (KTPs) received corticosteroid minimization with PR-T. METHODS: ADVANCE was a 24-wk, randomized, open-label, phase-4 study. De novo KTPs received PR-T with basiliximab and mycophenolate mofetil and were randomized to receive an intraoperative corticosteroid bolus plus tapered corticosteroids until day 10 (arm 1) or an intraoperative corticosteroid bolus (arm 2). In this 5-y, noninterventional follow-up, patients received maintenance immunosuppression according to standard practice. The primary endpoint was graft survival (Kaplan-Meier). Secondary endpoints included patient survival, biopsy-confirmed acute rejection-free survival, and estimated glomerular filtration rate (4-variable modification of diet in renal disease). RESULTS: Follow-up study included 1125 patients. Overall graft survival at 1 and 5 y posttransplantation was 93.8% and 88.1%, respectively, and was similar between treatment arms. At 1 and 5 y, patient survival was 97.8% and 94.4%, respectively. Five-year graft and patient survival rates in KTPs who remained on PR-T were 91.5% and 98.2%, respectively. Cox proportional hazards analysis demonstrated similar risk of graft loss and death between treatment arms. Five-year biopsy-confirmed acute rejection-free survival was 84.1%. Mean ± standard deviation values of estimated glomerular filtration rate were 52.7 ± 19.5 and 51.1 ± 22.4 mL/min/1.73 m2 at 1 and 5 y, respectively. Fifty adverse drug reactions were recorded, probably tacrolimus-related in 12 patients (1.5%). CONCLUSIONS: Graft survival and patient survival (overall and for KTPs who remained on PR-T) were numerically high and similar between treatment arms at 5 y posttransplantation.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Glyda, Maciej $u Department of Transplantology and Surgery, District Public Hospital Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Bydgoszcz, Poland
700    1_
$a Viklický, Ondrej $u Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Lõhmus, Aleksander $u Department of Urology and Kidney Transplantation, Clinic of Surgery, Tartu University Hospital, Tartu, Estonia
700    1_
$a Wennberg, Lars $u Department of Transplantation Surgery, Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Witzke, Oliver $u Department of Infectious Diseases, West German Centre of Infectious Diseases, University Hospital Essen, University Duisberg-Essen, Germany
700    1_
$a von Zur-Mühlen, Bengt $u Department of Surgical Sciences, Division of Transplantation Surgery, Uppsala University Hospital, Uppsala, Sweden
700    1_
$a Anaokar, Swapneel $u Medical Affairs, Astellas Pharma Europe, Chertsey, United Kingdom
700    1_
$a Hurst, Martin $u Medical Affairs, Astellas Pharma Europe, Chertsey, United Kingdom
700    1_
$a Kazeem, Gbenga $u Medical Affairs, Astellas Pharma Europe, Chertsey, United Kingdom $u BENKAZ Consulting Ltd, Cambridge, United Kingdom
700    1_
$a Undre, Nasrullah $u Medical Affairs, Astellas Pharma Europe, Chertsey, United Kingdom
700    1_
$a Kuypers, Dirk R J $u Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium
773    0_
$w MED00195744 $t Transplantation direct $x 2373-8731 $g Roč. 9, č. 3 (2023), s. e1432
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36875940 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230413 $b ABA008
991    __
$a 20230421100105 $b ABA008
999    __
$a ok $b bmc $g 1922666 $s 1188987
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 9 $c 3 $d e1432 $e 20230208 $i 2373-8731 $m Transplantation direct $n Transplant Direct $x MED00195744
LZP    __
$a Pubmed-20230413

Najít záznam

Citační ukazatele

Možnosti archivace